• EN/ES

    Orthopedics

    WebHealthNetwork : 2,378,479


  • Benefits & Savings

  • : Liposarcoma

Liposarcoma - 29 Studies Found

Active, not recruiting : Brostallicin Clinical Trial for Myxoid Liposarcoma
: Myxoid Liposarcoma
: 2008-03-03
: Drug: Brostallicin Patients will receive Brostallicin administered intravenously (IV) over 10 minutes at
Completed : Ph II Cabazitaxel DD Liposarcoma
: Dedifferentiated Liposarcoma
: 2013-07-30
:
  • Drug: Cabazitaxel Other Name:

Completed : Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma
: Liposarcoma
: 2015-01-05
:
  • Drug: HDM201
  • Drug: LEE011

Completed : Selinexor in Advanced Liposarcoma
: Dedifferentiated Liposarcoma
: 2015-10-13
:
  • Drug: Selinexor Selinexor 60mg

Completed : Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma
: Liposarcoma,Myxoid
: 2007-12-20
:
  • Drug: Trabectedin Trabectedin

Recruiting : Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery
: Liposarcoma
: 2014-09-24
: Drug: efatutazone Given PO
Completed : Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcomas
: Myxoid Liposarcoma of Soft Tissue
: 2014-03-06
: Radiation: dose reduction of preoperative radiotherapy in MLS A: The primary sarcoma in case of non-meta
Completed : Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma
:
  • Liposarcoma
  • Surgically Unresectable Lipos
    : 2012-01-06
    : Drug: pazopanib Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administ
Completed : MGCD516 in Advanced Liposarcoma and Other Soft Tissue Sarcomas
:
  • Liposarcoma
  • Metastatic Liposarcoma
    : 2016-11-29
    : Drug: MGCD516 Administered at 150 mg orally, daily, in continuous 21 day cycles. An orally available, po
Withdrawn : Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma
: Dedifferentiated Liposarcoma
: 2009-09-01
: Drug: IPI-504 IPI 504 administered twice weekly at 225 mg/m2 for 2 weeks followed by 1 week off treatmen
Next >>>
Orthopedics Health
Orthopedics Health WebHealth Network Media
  • WebHealthNetwork
  • DiabetesHealthMatters
  • HeartandStrokeHealth
  • WomensHealthCareCommunity
  • AsthmaHealthCenter
  • CancerHealthCenter
  • MentalHealthHelpCenter
  • Skincarehealthcenter
  • DigestiveTractHealth
  • VaccineHealthCenter
  • PainHealthCenter
  • FightingAddictionCenter
  • ObesityHealthMatters
  • SeniorHealthcareMatters
  • BrainAndNerveCenter
  • PediatricsHealthCenter
  • RareDiseasesHealthCenter
  • Wealth Mason
  • Home Owners Circle
  • EasyInsuranceFinder
  • EduJumpStart
  • SaleSpider
  • ScoopCafe
  • SaleSpiderMedia
  • Viewpoint.World
  • TravelerBooked
  • TechNewsBytes
  • Contact Us
  • Advertising Privacy Policy

This site uses cookies for analytics and advertising. No personal information is collected.

© Orthopedics Health .

We use cookies to enhance your experience, analyze anonymized traffic, and deliver personalized content and ads. No personal information is collected. By using our website, you consent to our use of cookies and agree to our data practices as described in our Privacy Policy. To Reject, please change your browser settings.